RxDoctor Payments Data

John Foley, MD

Ophthalmology · Saint Paul, MNNPI 1124133764

Payments from drug & device makers

What this record shows

This record is dominated by other: $3,040 of the $3,795 with a category attached, or 80.1%. Carl Zeiss Meditec, Inc. accounts for 80.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $3,190 and has fallen 90.7% since, to $296 in 2025.

$3,795in general payments, 2019–2025

Across 11 payments — averaging $345.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$3K
  • Glaukos Corporation$296
  • Alcon$264
  • AbbVie$157
  • Carl Zeiss Meditec AG$39

What the payments were for

  • Food & beverage$71719%
  • Gifts$391%
  • Other$3,04080%

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,795 in reported general payments places this provider in the 85th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$249,929
Medicare patients
570
Services billed
3,811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast96$118,710
RestasisCyclosporine87$104,252
RhopressaNetarsudil Mesylate191$91,880
Travoprost181$37,374
Cyclosporine52$35,495
VyzultaLatanoprostene Bunod82$34,070
Latanoprost1,137$20,590
LumiganBimatoprost43$17,783
Prednisolone Acetate288$15,030
Loteprednol Etabonate28$9,620
Brinzolamide38$9,090
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat357$8,718
IlevroNepafenac16$7,679
Timolol Maleate507$7,521
Timolol MaleateTimolol Maleate/Pf11$7,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$157$122,035130 claims
AlconSimbrinza$264$4,03117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →